Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.52 |
| ▸ | HTR2A | P28223 | 3/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.44 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.44 |
| ▸ | HRH1 | P35367 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19812637 | 0.83 | HRH1 (0.56) | TAAR1HTR2ACHRNB2CHRNA4GABBR2 | |
| SCHEMBL8712988 | 0.77 | LMNA (0.46) | TAAR1HTR2AHRH1 | |
| SCHEMBL11630123 | 0.77 | LMNA (0.38) | TAAR1HTR2AHRH1DPP4F2 | |
| SCHEMBL9220590 | 0.77 | HTR2A (0.36) | TAAR1HTR2AHRH1DPP4F2 | |
| SCHEMBL15259640 | 0.77 | TSHR (0.39) | TAAR1HTR2AHRH1DPP4F2 | |
| SCHEMBL4400769 | 0.77 | TRPA1 (0.41) | TAAR1HTR2A | |
| SCHEMBL143452 | 0.77 | LMNA (0.46) | TAAR1HTR2AHRH1 | |
| SCHEMBL6725218 | 0.77 | TAAR1 (0.52) | TAAR1HTR2ACHRNB2CHRNA4GABBR2 | |
| SCHEMBL1856265 | 0.77 | TAAR1 (0.52) | TAAR1HTR2ACHRNB2CHRNA4GABBR2 | |
| SCHEMBL832849 | 0.76 | EPHX1 (0.46) | TAAR1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1087642-A | Be used to discharge the method for cytotoxic agents and its component | HYBRITECH INC (US) | 1994-06-08 | — | — | CN | claimed |
| EP-0382411-A2 | Delivery of cytotoxic agents | ELI LILLY AND COMPANY (US) | 1990-08-16 | — | — | EP | claimed |
| US-4118566-A | Δ2,3 -1,4-Morpholine-2-carboxylic acid derivatives as antibacterial agents | BRISTOL-MYERS COMPANY (US) | 1978-10-03 | — | — | US | claimed |
| US-4112230-A | Δ2,3 -1,4 Morpholine-2-carboxylic acid derivatives as antibacterial agents | BRISTOL-MYERS COMPANY (US) | 1978-09-05 | — | — | US | claimed |
| US-20230322858-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | SPERO THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| EP-4029512-A1 | VARIANTS OF C-TYPE NATRIURETIC PEPTIDE | BioMarin Pharmaceutical Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| EP-3175863-B1 | VARIANTS OF C-TYPE NATRIURETIC PEPTIDE | BIOMARIN PHARM INC (US) | 2021-12-01 | — | — | EP | disclosed |
| US-20210221848-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | SPERO THERAPEUTICS, INC. | 2021-07-22 | — | — | US | disclosed |
| US-RE48267-E1 | Variants of C-type natriuretic peptide | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-10-20 | — | — | US | disclosed |
| EP-3175863-A1 | VARIANTS OF C-TYPE NATRIURETIC PEPTIDE | BioMarin Pharmaceutical Inc. (US) | 2017-06-07 | — | — | EP | disclosed |
| US-20170051033-A1 | Variants of C-Type Natriuretic Peptide | BIOMARIN PHARM INC (US) | 2017-02-23 | — | — | US | disclosed |
| EP-2432489-B1 | VARIANTS OF C-TYPE NATRIURETIC PEPTIDE | BIOMARIN PHARM INC (US) | 2016-10-05 | — | — | EP | disclosed |
| US-4066831-A | ANTIBIOTICS | BRISTOL-MYERS COMPANY (US) | 1978-01-03 | — | — | US | disclosed |
| US-4066832-A | ANTIBIOTICS | BRISTOL-MYERS COMPANY (US) | 1978-01-03 | — | — | US | disclosed |
| US-4065623-A | O-2-Isocephem-4-carboxylic acid derivatives as antibacterial agents | BRISTOL-MYERS COMPANY (US) | 1977-12-27 | — | — | US | disclosed |
| US-4065622-A | O-2-Isocephem-4-carboxylic acid derivatives as antibacterial agents | BRISTOL-MYERS COMPANY (US) | 1977-12-27 | — | — | US | disclosed |
| US-4013648-A | BETA-LACTAM ANTIBIOTICS | BRISTOL-MYERS COMPANY (US) | 1977-03-22 | — | — | US | disclosed |
| US-4013650-A | PROCESS FOR THE MANUFACTURE OF 3-METHYLENE-CEPHAM COMPOUNDS | CIBA-GEIGY CORPORATION (US) | 1977-03-22 | — | — | US | disclosed |
| US-4012383-A | BACTERICIDES | BRISTOL-MYERS COMPANY (US) | 1977-03-15 | — | — | US | disclosed |
| US-4011216-A | Δ2,3-0-2-Isocephem-4-carboxylic acid and derivatives thereof as antibacterial agents | BRISTOL-MYERS COMPANY (US) | 1977-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322858-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | PNISR, MRPS18A, RRP15 | TAAR1 1824/4885HTR2A 4343/4885CHRNB2 4882/4885 |
| US-20210221848-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | PNISR, MRPS18A, MRPS35 | TAAR1 1920/4885HTR2A 4391/4885CHRNB2 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.